<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02071160</url>
  </required_header>
  <id_info>
    <org_study_id>01012012</org_study_id>
    <nct_id>NCT02071160</nct_id>
  </id_info>
  <brief_title>Melatonin for Neuroprotection Following Perinatal Asphyxia</brief_title>
  <official_title>Melatonin for Neuroprotection Following Perinatal Asphyxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to examine the effect of combining melatonin to whole body cooling
      on the brain injury and outcome of neonates following perinatal asphyxia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study on 30 neonates with moderate to moderately to severe hypoxic
      ischemic encephalopathy (HIE) . HIE infants are randomized into two groups: Whole body
      cooling group (N = 15; receive 72 hours of whole body hypothermia) and melatonin/ hypothermia
      group (N = 15; receive hypothermia and 5 daily enteral doses of melatonin 10 mg/kg). Serum
      melatonin, plasma superoxide dismutase (SOD),and serum nitric oxide (NO) are measured at
      enrollment and after 2 weeks for the two HIE groups. The HIE groups underwent
      electroencephalography at enrollment and at 2 to 3 weeks. Brain MRI was performed after 2
      weeks of life. Neurologic evaluations and Denver Developmental Screening Test II assessments
      were performed at 6 months. A group of healthy newborns will be used as a control for
      baseline labs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum melatonin concentration (pg/ ml)</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma superoxide dismutase (SOD) activity (U/ml)</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum nitric oxide (NO) concentrations (µmol/L)</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of EEG abnormalities</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of MRI abnormalities</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormal neurological examination</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormal Denver Developmental Screening Test II</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Perinatal Asphyxia</condition>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>A group of healthy control without any history suggestive of perinatal asphyxia or other diseases, are enrolled to compare different laboratory measurements</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypothermia Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>HIE infants who will not receive melatonin and only receive routine cooling protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melatonin/ hypothermia group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIE infants who will receive melatonin in addition to the routine cooling protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>Melatonin is administered to the melatonin/hypothermia group (n=15) in a dose of 10 mg/kg daily for a total of 5 doses starting immediately at enrollment. Melatonin tablets (1 or 3 mg/tablet) (Puritan's Pride,Oakdale, NY, USA) are crushed, then dissolved in 5-10 ml of distilled water , then administered via an orogastric tube.</description>
    <arm_group_label>Melatonin/ hypothermia group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inborn infants at term gestation (38-42 weeks)

          -  Apgar scores ≤ 3 at 5 minutes and/or delayed first breath (&gt;5 minutes after birth)

          -  Profound metabolic or mixed acidosis with serum bicarbonate levels of &lt;12 mmol/L in
             initial blood gas analyses

          -  Evidence of moderate or moderate to severe encephalopathy, such as lethargy, seizures,
             abnormal reflexes, or hypotonia, in the immediate neonatal period

        Exclusion Criteria:

          -  Twin gestation

          -  Maternal neuro-endocrinal disturbances including diabetes mellitus

          -  Chorioamnionitis or congenital infections

          -  Low birth weight less than 2.5 kg

          -  Congenital malformations of the central nervous system or gastrointestinal anomalies

          -  Chromosomal abnormalities

          -  After 6 hours of birth.

          -  Patients in extremis such as: (1) hypoxemia requiring supplemental oxygen 100% FiO2,
             (2) life threatening coagulopathy, or (3) deep coma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Hours</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heba Mahdy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tanta University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tanta University Children's Hospital</name>
      <address>
        <city>Tanta</city>
        <state>Gharbeya</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Gitto E, Reiter RJ, Cordaro SP, La Rosa M, Chiurazzi P, Trimarchi G, Gitto P, Calabrò MP, Barberi I. Oxidative and inflammatory parameters in respiratory distress syndrome of preterm newborns: beneficial effects of melatonin. Am J Perinatol. 2004 May;21(4):209-16.</citation>
    <PMID>15168319</PMID>
  </reference>
  <reference>
    <citation>Gitto E, Romeo C, Reiter RJ, Impellizzeri P, Pesce S, Basile M, Antonuccio P, Trimarchi G, Gentile C, Barberi I, Zuccarello B. Melatonin reduces oxidative stress in surgical neonates. J Pediatr Surg. 2004 Feb;39(2):184-9; discussion 184-9.</citation>
    <PMID>14966737</PMID>
  </reference>
  <reference>
    <citation>Chen YC, Tain YL, Sheen JM, Huang LT. Melatonin utility in neonates and children. J Formos Med Assoc. 2012 Feb;111(2):57-66. doi: 10.1016/j.jfma.2011.11.024. Epub 2012 Feb 15. Review.</citation>
    <PMID>22370283</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2014</study_first_submitted>
  <study_first_submitted_qc>February 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2014</study_first_posted>
  <last_update_submitted>February 23, 2014</last_update_submitted>
  <last_update_submitted_qc>February 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Heba Mahdy</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>HIE</keyword>
  <keyword>hypothermia</keyword>
  <keyword>encephalopathy</keyword>
  <keyword>anti oxidants</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asphyxia</mesh_term>
    <mesh_term>Asphyxia Neonatorum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

